Rapid, Portable Dengue Virus Diagnostic

Tech ID: 24286 / UC Case 2015-017-0

Patent Status

Country Type Number Dated Case
United States Of America Published Application 170138956 05/18/2017 2015-017
Patent Cooperation Treaty Published Application WO2016070023 05/06/2016 2015-017

Brief Description

The 4 dengue virus serotypes (DENV1-4) cause the most prevalent mosquito-borne viral illness in humans with up to 96 million cases annually worldwide.  Dengue virus infections can result in a range of clinical manifestations from asymptomatic infection to dengue fever (DF) and the severe disease dengue hemorrhagic fever/dengue shock syndrome.  Thus, there is a need for accurate, specific, inexpensive Dengue diagnostic test that can be used for early detection and treatment and can be used for surveillance and outbreak investigations.    


UC Researchers have developed an assay that can be used to identify serotype-specific and cross-reactive B cells in DENV-infected individuals as well as in vaccines.  The assay allows detection of B cell antigen specificity to the four different pathogen serotypes on a per-cell basis and allows visualization of serotype cross-reactivity versus type-specificity per cell.


Suggested uses

  • Diagnostic assay for the four different serotypes on a per-cell basis
  • Assay for the different isotypes of immunoglobulins directed against DENV envelope protein
  • Testing the efficiency of vaccines in generating a full B cell response against DENV envelope protein 
  • Comparing cross-reactivity of the B cell population between individuals with naturally acquired dengue immunity to recipieints of candidate dengue vaccines


  • Allows visualization of serotype cross-reactivity versus type-specificity per cell
  • Use of fluorescent dyes instead of enzymatic reaction increases the sensitivity and reduces the background 
  • Enables quantification of the breadth, magnitude, specificity and cross-reactivity of B cell responses following sequential DENV infections

State Of Development

The assay has been validated with both peripheral blood mononuclear cells from human DENV-immune individuals as well as serotype-specific and cross-reactive human monoclonal antibody hybridomas.

Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Harris, Eva

Other Information


Dengue, DENV, diagnostic, infectious disease, Elispot, immunoassay, point of care, POC

Categorized As